Alnylam Pharma share price logo

Alnylam Pharma

NASDAQ: ALNY

Large Cap

$165.00

-9.00

(-5.17%)

as on

Alnylam Pharma Stock Performance

as on November 2, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $163.30
    $180.39
    downward going graph

    1.03%

    Downside

    9.33%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $163.30
    $479.79
    downward going graph

    1.03%

    Downside

    190.78%

    Upside

    downward going graph

Alnylam Pharma share price movements today

Previous Close
$174.00
Open
$172.69
Volume
6.2M
Market Cap
$22.1B
Day's Low - High
$163.30 - $180.39
52 Week Low - High
$163.30 - $479.79

Alnylam Pharma Historical Returns

1 Month Return
-24.9 %
3 Month Return
-19.72 %
1 Year Return
-63.82 %
3 Year Return
+ 2.15 %
5 Year Return
-1.58 %

Alnylam Pharma Stock Fundamentals & Key Indicators

Check Alnylam Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$22.1B

EPS (TTM)

20.38

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

6.33%

PE Ratio (TTM)

8.1

Industry PE ratio

6.81

PEG Ratio

0.00

EBITDA

1.2B

Revenue (TTM)

5.0B

Profit Margin

77.28%

Return On Equity TTM

159.72%

Alnylam Pharma vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Alnylam Pharma with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Alnylam Pharma image
Alnylam Pharma
StrongBuy$22.1B-1.58%8.1077.28%0.00%
Moderna image
Moderna
Neutral$88.5B-36.40%-27.78-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$141.7B208.09%32.2786.04%0.00%
Regeneron image
Regeneron
Buy$95.5B45.26%19.7685.77%0.40%

Stock Returns calculator for Alnylam Pharma Stock including INR - Dollar returns

The Alnylam Pharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Alnylam Pharma investment value today

Current value as on today

₹38,700

Returns

-₹61,300

(-61.3%)

Returns from Alnylam Pharma Stock

-₹63,819 (-63.82%)

Dollar Impact

₹2,519 (+2.52%)

Analyst Recommendation on Alnylam Pharma Stock

Based on 16 analysts

BUY

81.25%

Buy

18.75%

Hold

0.00%

Sell

Based on 16 analysts, 81.25% of analysts recommend a 'BUY' rating for Alnylam Pharma. Average target price of $314.81

Alnylam Pharma Share Price Target

Get share price movements and forecasts by analysts on Alnylam Pharma.

What analysts predicted

47.59%UPSIDE

Target Price

$314.81

Current Price

$165

Analyzed by

16 Analysts

High

$455

Target

$314.81

Low

$220

Alnylam Pharma target price $314.81, a slight upside of 47.59% compared to current price of $165. According to 16 analysts rating.

Indian Investors' Interest in Alnylam Pharma Stock

Search interest for Alnylam Pharma Stock has increased by 35% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:35% versus previous 30 day period

Alnylam Pharma Quarterly Profit & Loss

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Revenue
659
500
593
594
773
1,249
1,097
1,167
1,290
1,458
Gross Profit
591
415
490
523
630
1,051
829
956
992
1,096
Operating Income
48
-76
-105
18
-16
367
131
268
231
345
EBITDA
37
-60
-140
11
18
297
303
304
245
394
Interest Expense
33
34
38
38
40
44
129
69
82
84
Depreciation
15
13
14
14
13
13
13
13
13
14
Income Before Tax
-11
-108
-193
-41
-35
238
161
221
177
295
Income Tax Expense
5
2
-110
15
30
-12
-25
-15
13
-1,871
Net Income
-16
-111
-83
-57
-66
251
186
205
164
2,167
Net Profit Margin
89.59%
82.85%
82.67%
88.04%
81.52%
84.21%
75.60%
81.91%
76.90%
75.19%

Alnylam Pharma Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
89
74
219
492
844
1,037
1,828
2,248
3,713
Gross Profit
76
73
194
414
704
868
1,517
1,924
3,036
Operating Income
-500
-814
-939
-828
-708
-785
-282
-176
501
EBITDA
-488
-754
-830
-696
-661
-926
-258
-178
631
Interest Expense
-
-
-
84
143
155
121
141
252
Depreciation
13
6
54
74
47
44
54
56
55
Income Before Tax
-490
-760
-885
-855
-852
-1,126
-433
-377
323
Income Tax Expense
-
0
0
2
0
4
6
-99
9
Net Income
-490
-761
-886
-858
-852
-1,131
-440
-278
313
Net Profit Margin
85.13%
97.59%
88.60%
84.16%
83.40%
83.73%
83.02%
85.62%
81.77%

Alnylam Pharma Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Net Income
-16
-111
-83
-57
-66
251
186
205
164
2,167
Operating Cash Flow
124
43
-94
-118
153
325
163
70
75
340
Investing Cash Flow
33
-30
-52
113
-141
501
-37
-25
-363
-311
Financing Cash Flow
131
102
30
44
53
-448
45
15
23
18
Change in Cash
286
131
-133
53
93
376
166
53
-267
46

Alnylam Pharma Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-490
-761
-886
-858
-852
-1,131
-440
-278
313
Operating Cash Flow
-382
-562
-278
-614
-641
-541
104
-8
524
Investing Cash Flow
-290
272
-417
-435
-273
169
-336
-116
436
Financing Cash Flow
1,124
65
823
994
1,247
425
172
294
-305
Change in Cash
451
-224
126
-50
323
46
-53
153
690

Global Institutional Holdings in Alnylam Pharma

Check out the Institutions with significant holdings in Alnylam Pharma.

Funds
Holdings
Vanguard
9.48%
VANGUARD INDEX FUNDS
8.57%
Growth Fund of America
6.70%
iShares
5.05%
AMCAP Fund
3.38%
See all

Alnylam Pharma News & Key Events

  • img

    Today's Timeline - 02 November

    Mon, 03:55 PM

    -

    Barclays lowers Alnylam price target to $380 from $450, maintaining Overweight rating amid Amvuttra commercial uncertainty.

    Mon, 04:06 PM

    -

    Alnylam's Cemdisiran shows significant improvements in Phase 3 trial, potentially earning royalties of up to 15% on worldwide sales.

    Mon, 04:15 PM

    -

    Truist downgrades Alnylam to Hold from Buy, citing uncertain Amvuttra outlook and lowering price target to $225.

  • img

    Today's Timeline - 02 November

    Mon, 05:46 PM

    -

    Canaccord lowers Alnylam price target to $323 from $429, keeps Buy rating amid cautious Amvuttra launch commentary.

Insights on Alnylam Pharma

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 1.09B → 1.45B (in $), with an average increase of 9.0% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 164.49M → 2.16B (in $), with an average increase of 92.4% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 716.3% return, outperforming this stock by 780.1%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 211.3% return, outperforming this stock by 209.2%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, ALNY stock has moved down by -27.5%

About Alnylam Pharma

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
OrganisationAlnylam Pharma
Headquarters675 West Kendall Street, Cambridge, MA, 02142, US
IndustryBiotechnology
CEOYvonne L. Greenstreet

Key Management of Alnylam Pharma

Name

Title

Dr. Yvonne L. Greenstreet M.B.A., M.D.

CEO & Director

Mr. Bryan Andrew Supran J.D.

Chief Legal Officer

Dr. Pushkal P. Garg M.D.

Executive VP & Chief Research & Development Officer

Mr. Tolga Tanguler M.B.A.

Executive VP & Chief Commercialization Officer

Mr. Timothy J. Maines

Chief Technical Operations & Quality Officer

Dr. Kevin Joseph Fitzgerald Ph.D.

Executive VP, Chief Scientific Officer and Head of Early Research & Early Development

Mr. Joshua Brodsky

Vice President of Investor Relations

Mr. Piyush Sharma J.D.

Chief Ethics & Compliance Officer

Dr. Phillip A. Sharp Ph.D.

Co-Founder, Member of the Scientific Advisory Board

Mr. Jeffrey V. Poulton M.B.A.

CFO & Executive VP

FAQs

What is Alnylam Pharma share price today?

Alnylam Pharma share price today is $165.00 as on at the close of the market. Alnylam Pharma share today touched a day high of $180.39 and a low of $163.30.

What is the 52 week high and 52 week low for Alnylam Pharma share?

Alnylam Pharma share touched a 52 week high of $479.79 on and a 52 week low of $163.30 on . Alnylam Pharma stock price today i.e. is closed at $165.00,which is 65.61% down from its 52 week high and 1.04% up from its 52 week low.

What is Alnylam Pharma's market capitalisation today?

Alnylam Pharma market capitalisation is $0.02T as on .

How to invest in Alnylam Pharma Stock (ALNY) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Alnylam Pharma on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Alnylam Pharma Stock (ALNY) from India?

Indian investors can start investing in Alnylam Pharma (ALNY) shares with as little as ₹94.9000015258789 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.00 in Alnylam Pharma stock (as per the Rupee-Dollar exchange rate as on ). Based on Alnylam Pharma share’s latest price of $165.00 as on November 2, 2026 at 8:46 am IST, you will get 0.0606 shares of Alnylam Pharma. Learn more about fractional shares .

What are the returns that Alnylam Pharma has given to Indian investors in the last 5 years?

Alnylam Pharma stock has given -1.58% share price returns and 27.07% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?